Finally, we assessed immune checkpoint therapy in patients with ccRCC and found that the high riskscore group presented better IPS involving CTLA4 and PD1/PDL1/PDL2 combination blockades. This evidence concerns the gene CTLA4 and nonpapillary renal cell carcinoma.